Alternating combination chemotherapy of advanced soft tissue sarcomas in adults
- 1 October 1984
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 7 (5) , 539-542
- https://doi.org/10.1097/00000421-198410000-00029
Abstract
THE POSSIBILITY OF IMPROVING TREATMENT RESULTS using an alternating combination chemotherapy was explored in 40 evaluable patients with advanced soft tissue sarcomas. Treatment regimen consisted of adriamycin and DTIC alternating with vincristine, actinomycin D, and cy-clophosphamide. Four patients achieved a complete response and eight achieved a partial response, with an overall response rate of 30%. The median duration of response was 14 months. The median survival time was 28 months for responders compared with 7 months for nonresponders (p = 0.001). Toxicity was predominantly limited to nausea, vomiting, and myelosuppression. Although this alternating regimen failed to improve response rates over other combinations, survival times observed in the present study should provide impetus to evaluate further the concept of sequential noncross-resistant combinations.This publication has 8 references indexed in Scilit:
- A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcomaCancer, 1982
- Combination chemotherapy of advanced sarcomas in adults with “CYOMAD” (S7)Cancer, 1982
- RATIONALE FOR THE USE OF ALTERNATING NON-CROSS-RESISTANT CHEMOTHERAPY1982
- Metastatic sarcomas: Chemotherapy with adriamycin, cyclophosphamide, and methotrexate alternating with actinomycin D, DTIC, and vincristineCancer, 1981
- CYCLICAL COMBINATION CHEMOTHERAPEUTIC REGIMEN IN ADULT SOFT-TISSUE SARCOMA1981
- Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD)Cancer, 1980
- RESULTS OF THE ROYAL-MARSDEN-HOSPITAL 2ND SOFT-TISSUE SARCOMA SCHEDULE (STS-II) CHEMOTHERAPY REGIMEN IN THE MANAGEMENT OF ADVANCED SARCOMA1980
- COMPARATIVE CLINICAL-TRIAL EVALUATING COMBINATION OF ADRIAMYCIN, DTIC, AND VINCRISTINE, COMBINATION OF ACTINOMYCIN-D, CYCLOPHOSPHAMIDE, AND VINCRISTINE, AND A SINGLE AGENT, METHYL-CCNU, IN ADVANCED SARCOMAS1976